Why is Godavari Drugs falling/rising?

As of 25-Jul, Godavari Drugs Ltd is currently priced at 87.53, reflecting a slight increase of 0.21 or 0.24%. Despite this minor uptick, the stock has been underperforming, with a 1-month return of -6.27% and a year-to-date decline of -19.95%. Today's trading performance indicates that the stock is below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 52.18% compared to the 5-day average. The company's fundamentals are concerning, as it has reported a decline in profits by 22.1% over the past year, and its recent financial results show a substantial decrease in both net sales and profit after tax.
In the broader market context, Godavari Drugs has not only underperformed against the Sensex, which has gained 4.25% year-to-date, but it has also lagged behind in the longer term, with a 3-year return of +26.03% compared to the benchmark's +46.08%. The stock's weak long-term fundamentals, highlighted by a high debt-to-EBITDA ratio and a low growth rate in operating profits, further contribute to its negative outlook. Overall, while the stock has seen a minor increase today, the persistent underperformance and negative financial indicators suggest that the upward movement may not be sustainable in the face of broader market trends and company-specific challenges.